ORCHID PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,093 INR | +1.20% |
|
+7.23% | +53.47% |
Valuation
| Fiscal Period: March | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 55,459 | - | - |
| Enterprise Value (EV) 1 | 54,403 | 54,262 | 54,074 |
| P/E ratio | 60.6 x | 39.1 x | 22.5 x |
| Yield | - | - | - |
| Capitalization / Revenue | 6.57 x | 5.14 x | 3.29 x |
| EV / Revenue | 6.44 x | 5.03 x | 3.2 x |
| EV / EBITDA | 46.6 x | 31.5 x | 16.4 x |
| EV / FCF | -134 x | -28.5 x | 187 x |
| FCF Yield | -0.75% | -3.51% | 0.54% |
| Price to Book | 4.72 x | 4.14 x | 3.81 x |
| Nbr of stocks (in thousands) | 50,719 | - | - |
| Reference price 2 | 1,093 | 1,093 | 1,093 |
| Announcement Date | - | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | 8,445 | 10,780 | 16,881 |
| EBITDA 1 | - | 1,166 | 1,721 | 3,293 |
| EBIT 1 | - | 794.5 | 1,160 | 2,176 |
| Operating Margin | - | 9.41% | 10.77% | 12.89% |
| Earnings before Tax (EBT) 1 | - | 911.3 | 1,427 | 2,648 |
| Net income 1 | 463.2 | 908.3 | 1,422 | 2,549 |
| Net margin | - | 10.76% | 13.19% | 15.1% |
| EPS 2 | - | 18.03 | 27.93 | 48.63 |
| Free Cash Flow 1 | - | -407 | -1,907 | 289.5 |
| FCF margin | - | -4.82% | -17.69% | 1.71% |
| FCF Conversion (EBITDA) | - | - | - | 8.79% |
| FCF Conversion (Net income) | - | - | - | 11.36% |
| Dividend per Share | - | - | - | - |
| Announcement Date | 10/05/23 | - | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: Maart | 2024 Q3 | 2024 Q4 |
|---|---|---|
| Net sales 1 | 2,098 | 2,524 |
| EBITDA 1 | 265.5 | 404 |
| EBIT | - | - |
| Operating Margin | - | - |
| Earnings before Tax (EBT) | - | - |
| Net income 1 | 201 | - |
| Net margin | 9.58% | - |
| EPS 2 | 4.000 | - |
| Dividend per Share | - | - |
| Announcement Date | - | - |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: Maart | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | - | 1,056 | 1,197 | 1,385 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | - | -407 | -1,907 | 290 |
| ROE (net income / shareholders' equity) | - | 9.07% | 11% | 16.6% |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share 2 | - | 231.0 | 264.0 | 287.0 |
| Cash Flow per Share | - | - | - | - |
| Capex 1 | - | 1,750 | 6,549 | 1,855 |
| Capex / Sales | - | 20.72% | 60.75% | 10.99% |
| Announcement Date | 10/05/23 | - | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1,093
INR
Average target price
1,130
INR
Spread / Average Target
+3.34%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +53.47% | 656M | |
| +32.09% | 694B | |
| +29.39% | 593B | |
| -1.34% | 371B | |
| +20.34% | 331B | |
| +7.39% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +10.02% | 209B | |
| +8.49% | 169B |
- Stock Market
- Equities
- ORCHPHARMA Stock
- Financials Orchid Pharma Limited
